
Has the outlook improved for amifostine as a clinical radioprotector.
Publication
, Journal Article
Wasserman, TH; Brizel, DM
Published in: Radiother Oncol
September 2001
Duke Scholars
Published In
Radiother Oncol
DOI
ISSN
0167-8140
Publication Date
September 2001
Volume
60
Issue
3
Start / End Page
334 / 336
Location
Ireland
Related Subject Headings
- Radiation-Protective Agents
- Oncology & Carcinogenesis
- Humans
- Head and Neck Neoplasms
- Amifostine
- 5105 Medical and biological physics
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wasserman, T. H., & Brizel, D. M. (2001). Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol, 60(3), 334–336. https://doi.org/10.1016/s0167-8140(01)00402-9
Wasserman, T. H., and D. M. Brizel. “Has the outlook improved for amifostine as a clinical radioprotector.” Radiother Oncol 60, no. 3 (September 2001): 334–36. https://doi.org/10.1016/s0167-8140(01)00402-9.
Wasserman TH, Brizel DM. Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol. 2001 Sep;60(3):334–6.
Wasserman, T. H., and D. M. Brizel. “Has the outlook improved for amifostine as a clinical radioprotector.” Radiother Oncol, vol. 60, no. 3, Sept. 2001, pp. 334–36. Pubmed, doi:10.1016/s0167-8140(01)00402-9.
Wasserman TH, Brizel DM. Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol. 2001 Sep;60(3):334–336.

Published In
Radiother Oncol
DOI
ISSN
0167-8140
Publication Date
September 2001
Volume
60
Issue
3
Start / End Page
334 / 336
Location
Ireland
Related Subject Headings
- Radiation-Protective Agents
- Oncology & Carcinogenesis
- Humans
- Head and Neck Neoplasms
- Amifostine
- 5105 Medical and biological physics
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 0299 Other Physical Sciences